Nano-X Imaging Ltd.

Code

S

Shares

469

Price

$1.65

Footnotes

6

The transaction reported in this row involved the sale of ordinary shares to cover tax liabilities arising from the vesting of restricted share units ("RSUs"). The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer that began vesting on December 10, 2024. Currently, 6,753 ordinary shares constitute the remainder of the ordinary shares held by, or issuable to, the Reporting Person under the subject grant. The 7,792 RSUs originally granted vest (and settle for underlying ordinary shares) on an equal, quarterly basis over twelve calendar quarters (for 649.33 underlying ordinary shares per quarter) such that all such 7,792 RSUs - reduced by RSUs for which underlying shares have been sold to cover tax liability - will be vested by December 10, 2027. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer that began vesting on December 10, 2025. Currently, 17,075 ordinary shares constitute the remainder of the ordinary shares held by, or issuable to, the Reporting Person under the subject grant. The 17,544 RSUs originally granted vest (and settle for underlying ordinary shares) on an equal, quarterly basis over twelve calendar quarters (for 1,462 underlying ordinary shares per quarter) such that all such 17,544 RSUs - reduced by RSUs for which underlying shares have been sold to cover tax liability - will be vested by December 10, 2028. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the date of appointment of the Reporting Person to the Issuer's Board of Directors on June 30, 2022, such that all options reported in this row will be exercisable by the four-year anniversary of that appointment date (June 30, 2026). The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable by the four-year anniversary of that grant approval date (August 14, 2027).